FOLD up +15.11% percent Today $FOLD High is at 6.70 and the Low 6.24 with current volume of 1,624,697.
Recent News posted below.
Amicus Therapeutics FOLD other info.
http://investorshangout.com/Amicus-Therapeutics-FOLD-54154/
FOLD Amicus Therapeutics Recent Headline News
Amicus Therapeutics (FOLD) Stock Surges Following Fabry Treatment Pill Results
at The Street - 34 mins ago
Shares of Amicus Therapeutics (FOLD) rose in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.
FOLD: 6.58 (+0.89)
Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
at The Street - 1 hr 59 mins ago
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
FOLD: 6.58 (+0.89)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - 2 hrs 46 mins ago
CADC: 5.88 (+1.62), INO: 10.12 (-0.88), CLDX: 18.30 (+4.14), HAL: 50.01 (-5.07), ROX: 1.84 (-0.14), SNSS: 2.35 (+0.68), DNR: 9.90 (-1.30), DWA: 22.17 (-3.85), GSAT: 2.83 (-0.14), CMGE: 26.18 (+0.58), FOLD: 6.58 (+0.89), BHI: 66.03 (+6.14)
Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST
SHPG: 204.80 (+2.18), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)
Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 204.80 (+2.18), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology
GlobeNewswire - Sat Nov 15, 9:00AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat"
for Fabry disease. In a poster at the American Society of Nephrology (ASN) Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy (ERT) to migalastat as their only therapy for Fabry disease. A slide presentation featuring these data is also available at http://ir.amicustherapeutics.com/events.cfm.
FOLD: 6.58 (+0.89)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 3.59 (-0.37), OPK: 8.26 (-0.03), PTCT: 39.36 (+0.47), ATHX: 1.36 (-0.01), FOLD: 6.58 (+0.89)
Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 8:50AM CST
FOLD: 6.58 (+0.89)
Amicus Therapeutics posts 3Q loss
Automated Insights - Thu Nov 06, 5:30PM CST
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $17.1 million, or 22 cents per share, in its third quarter.
FOLD: 6.58 (+0.89)
Amicus Therapeutics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:13PM CST
FOLD: 6.58 (+0.89)
Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Thu Nov 06, 3:01PM CST
Important New Migalastat Data on Cardiac and Other Key Secondary Endpoints for Study 012 to be Presented At American Society of Nephrology Meeting on November 15
FOLD: 6.58 (+0.89)
Amicus reports November 6
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 10:10AM CST
FOLD: 6.58 (+0.89)
Amicus Therapeutics Announces Timing of Third Quarter 2014 Financial Results, Upcoming Scientific Conference and Other Corporate Updates
GlobeNewswire - Mon Nov 03, 7:37AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that a conference call and live audio webcast are scheduled for Thursday, November 6, 2014 at 5:00 p.m. ET to discuss financial results for the third quarter ended September 30, 2014.
FOLD: 6.58 (+0.89)
InsiderInsights.com Daily Round Up 10/28/14: POL, NHF, SLB, ATI
InsiderInsights - at Seeking Alpha - Wed Oct 29, 5:58AM CDT
CLUB: 5.64 (-0.02), GD: 142.32 (-0.34), ATI: 32.31 (-0.54), CACC: 159.66 (-0.90), HSON: 3.18 (-0.19), AAMC: 480.10 (-0.90), BMY: 58.13 (+0.18), SLB: 95.66 (+0.34), MXWL: 10.71 (-0.49), POL: 36.77 (+0.09), BTU: 11.30 (-0.09), NOW: 64.96 (-2.55), OMAM: 15.77 (+0.20), TYL: 110.00 (-0.46), NHF: 11.30 (+0.12), FBC: 15.46 (-0.26), ACN: 84.48 (-0.16), FOLD: 6.58 (+0.89), SWHC: 9.55 (-0.10)
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 8.70 (+0.22), PGNX: 6.47 (+0.14), IDRA: 2.40 (-0.05), THLD: 2.93 (+0.06), FOLD: 6.58 (+0.89)
Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 8.62 (+0.08), EBS: 24.41 (+0.19), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 305.18 (-0.25), MNOV: 3.03 (-0.04), CHTP: 6.52 (-0.03), ADMS: 14.56 (-0.27), ACOR: 34.08 (+0.61), BCLI: 3.37 (-0.10), BSX: 13.39 (+0.03), IPXL: 28.83 (-0.03), AVNR: 13.25 (+0.12), ACAD: 27.27 (+0.13), CVTS: (), MRK: 59.54 (+0.47), TEVA: 57.60 (+0.53), PRTA: 22.02 (+0.49), PRAN: 1.70 (-0.03), FOLD: 6.58 (+0.89), CUR: 2.85 (-0.01)
Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011
GlobeNewswire - Sun Oct 19, 6:00PM CDT
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR)
FOLD: 6.58 (+0.89)
Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable
GlobeNewswire - Tue Sep 30, 8:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET.
FOLD: 6.58 (+0.89)
Recent News posted below.
Amicus Therapeutics FOLD other info.
http://investorshangout.com/Amicus-Therapeutics-FOLD-54154/
FOLD Amicus Therapeutics Recent Headline News
Amicus Therapeutics (FOLD) Stock Surges Following Fabry Treatment Pill Results
at The Street - 34 mins ago
Shares of Amicus Therapeutics (FOLD) rose in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.
FOLD: 6.58 (+0.89)
Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
at The Street - 1 hr 59 mins ago
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
FOLD: 6.58 (+0.89)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - 2 hrs 46 mins ago
CADC: 5.88 (+1.62), INO: 10.12 (-0.88), CLDX: 18.30 (+4.14), HAL: 50.01 (-5.07), ROX: 1.84 (-0.14), SNSS: 2.35 (+0.68), DNR: 9.90 (-1.30), DWA: 22.17 (-3.85), GSAT: 2.83 (-0.14), CMGE: 26.18 (+0.58), FOLD: 6.58 (+0.89), BHI: 66.03 (+6.14)
Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST
SHPG: 204.80 (+2.18), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)
Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 204.80 (+2.18), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology
GlobeNewswire - Sat Nov 15, 9:00AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat"
for Fabry disease. In a poster at the American Society of Nephrology (ASN) Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy (ERT) to migalastat as their only therapy for Fabry disease. A slide presentation featuring these data is also available at http://ir.amicustherapeutics.com/events.cfm. FOLD: 6.58 (+0.89)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 3.59 (-0.37), OPK: 8.26 (-0.03), PTCT: 39.36 (+0.47), ATHX: 1.36 (-0.01), FOLD: 6.58 (+0.89)
Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 8:50AM CST
FOLD: 6.58 (+0.89)
Amicus Therapeutics posts 3Q loss
Automated Insights - Thu Nov 06, 5:30PM CST
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $17.1 million, or 22 cents per share, in its third quarter.
FOLD: 6.58 (+0.89)
Amicus Therapeutics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:13PM CST
FOLD: 6.58 (+0.89)
Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Thu Nov 06, 3:01PM CST
Important New Migalastat Data on Cardiac and Other Key Secondary Endpoints for Study 012 to be Presented At American Society of Nephrology Meeting on November 15
FOLD: 6.58 (+0.89)
Amicus reports November 6
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 10:10AM CST
FOLD: 6.58 (+0.89)
Amicus Therapeutics Announces Timing of Third Quarter 2014 Financial Results, Upcoming Scientific Conference and Other Corporate Updates
GlobeNewswire - Mon Nov 03, 7:37AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that a conference call and live audio webcast are scheduled for Thursday, November 6, 2014 at 5:00 p.m. ET to discuss financial results for the third quarter ended September 30, 2014.
FOLD: 6.58 (+0.89)
InsiderInsights.com Daily Round Up 10/28/14: POL, NHF, SLB, ATI
InsiderInsights - at Seeking Alpha - Wed Oct 29, 5:58AM CDT
CLUB: 5.64 (-0.02), GD: 142.32 (-0.34), ATI: 32.31 (-0.54), CACC: 159.66 (-0.90), HSON: 3.18 (-0.19), AAMC: 480.10 (-0.90), BMY: 58.13 (+0.18), SLB: 95.66 (+0.34), MXWL: 10.71 (-0.49), POL: 36.77 (+0.09), BTU: 11.30 (-0.09), NOW: 64.96 (-2.55), OMAM: 15.77 (+0.20), TYL: 110.00 (-0.46), NHF: 11.30 (+0.12), FBC: 15.46 (-0.26), ACN: 84.48 (-0.16), FOLD: 6.58 (+0.89), SWHC: 9.55 (-0.10)
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 8.70 (+0.22), PGNX: 6.47 (+0.14), IDRA: 2.40 (-0.05), THLD: 2.93 (+0.06), FOLD: 6.58 (+0.89)
Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 8.62 (+0.08), EBS: 24.41 (+0.19), SNY: 47.43 (+0.75), FOLD: 6.58 (+0.89)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 305.18 (-0.25), MNOV: 3.03 (-0.04), CHTP: 6.52 (-0.03), ADMS: 14.56 (-0.27), ACOR: 34.08 (+0.61), BCLI: 3.37 (-0.10), BSX: 13.39 (+0.03), IPXL: 28.83 (-0.03), AVNR: 13.25 (+0.12), ACAD: 27.27 (+0.13), CVTS: (), MRK: 59.54 (+0.47), TEVA: 57.60 (+0.53), PRTA: 22.02 (+0.49), PRAN: 1.70 (-0.03), FOLD: 6.58 (+0.89), CUR: 2.85 (-0.01)
Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011
GlobeNewswire - Sun Oct 19, 6:00PM CDT
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR)
FOLD: 6.58 (+0.89)
Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable
GlobeNewswire - Tue Sep 30, 8:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET.
FOLD: 6.58 (+0.89)
